Literature DB >> 30508596

A positive feedback regulation of Heme oxygenase 1 by CELF1 in cardiac myoblast cells.

Yang Liu1, Huiwen Wang2, Jun Wang1, Bin Wei3, Xinyi Zhang1, Mengqi Zhang1, Dong Cao4, Jiang Dai5, Zhen Wang6, Eric Nyirimigabo1, Guangju Ji7.   

Abstract

As an RNA binding protein, CUG-BP Elav-like family (CELF) has been shown to be critical for heart biological functions. However, no reports have revealed the function of CELF1 in hypertrophic cardiomyopathy (HCM). Hinted by RNA immunoprecipitation-sequencing (RIP-seq) data, the influence of the CELF protein on heme oxygenase-1 (HO-1) expression was tested by modulating CELF1 levels. Cardiac hypertrophy is related to oxidative stress-induced damage. Hence, the cardiovascular system may be protected against further injury by upregulating the expression of antioxidant enzymes, such as HO-1. During the past two decades, research has demonstrated the central role of HO-1 in the protection against diseases. Thus, understanding the molecular mechanisms underlying the modulation of HO-1 expression is profoundly important for developing new strategies to prevent cardiac hypertrophy. To elucidate the molecular mechanisms underlying HO-1 regulation by the CELF protein, we performed RNA immunoprecipitation (RIP), biotin pull-down analysis, luciferase reporter and mRNA stability assays. We found that the expression of HO-1 was downregulated by CELF1 through the conserved GU-rich elements (GREs) in HO-1 3'UTR transcripts. Correspondingly, CELF1 expression was regulated by controlling the release of carbon monoxide (CO) in H9C2 cells. The CELF1-HO-1-CO regulation axis constituted a novel positive feedback circuit. In addition, we detected the potential involvement of CELF1 and HO-1 in samples from HCM patients. We found that CELF1 and CELF2, but not HO-1, were highly expressed in HCM heart samples. Thus, a manipulation targeting CELF1 could be developed as a potential therapeutic option for cardiac hypertrophy.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CELF1; CO; GU-rich elements; HO-1; Hypertrophic cardiomyopathy

Mesh:

Substances:

Year:  2018        PMID: 30508596     DOI: 10.1016/j.bbagrm.2018.11.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta Gene Regul Mech        ISSN: 1874-9399            Impact factor:   4.490


  7 in total

Review 1.  Correction of RNA-Binding Protein CUGBP1 and GSK3β Signaling as Therapeutic Approach for Congenital and Adult Myotonic Dystrophy Type 1.

Authors:  Lubov Timchenko
Journal:  Int J Mol Sci       Date:  2019-12-21       Impact factor: 5.923

2.  LncRNA CCDC26 Interacts with CELF2 Protein to Enhance Myeloid Leukemia Cell Proliferation and Invasion via the circRNA_ANKIB1/miR-195-5p/PRR11 Axis.

Authors:  Chengliang Li; Jianjun Mu; Yingpeng Shi; Hong Xin
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

3.  CUGBP1, a crucial factor for heart regeneration in mice.

Authors:  Yang Liu; Huiwen Wang; Han Zhang; Jun Wang; Qun Liu; Youkun Bi; Shaole Song; Xinlong Qiao; Keqi Zhu; Yanyun Wu; Guangju Ji
Journal:  Cell Death Dis       Date:  2022-02-08       Impact factor: 8.469

4.  CELF1 promotes matrix metalloproteinases gene expression at transcriptional level in lens epithelial cells.

Authors:  Jun Xiao; Xin Tian; Siyan Jin; Yanhui He; Meijiao Song; He Zou
Journal:  BMC Ophthalmol       Date:  2022-03-14       Impact factor: 2.209

Review 5.  Cardiac function dependence on carbon monoxide.

Authors:  Vicki L Mahan
Journal:  Med Gas Res       Date:  2020 Jan-Mar

Review 6.  Reactive Oxygen Species Induced Pathways in Heart Failure Pathogenesis and Potential Therapeutic Strategies.

Authors:  Aušra Mongirdienė; Laurynas Skrodenis; Leila Varoneckaitė; Gerda Mierkytė; Justinas Gerulis
Journal:  Biomedicines       Date:  2022-03-03

Review 7.  mRNA Metabolism in Cardiac Development and Disease: Life After Transcription.

Authors:  Chen Gao; Yibin Wang
Journal:  Physiol Rev       Date:  2019-11-21       Impact factor: 37.312

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.